Thrombocytopenia in Chronic Liver Disease

Presenters:

April Morris, NP
Hunter Holmes McGuire VA Medical Center
Richmond, VA

Janet Jezsik, PA
Duke University
Durham, NC

Beginning Date: 10/31/2019
Ending Date: 10/31/2020

Webcast

Webcast must be viewed in its entirety to claim credit.

Accredited by:

Supported by:

This activity is supported by an educational grant from Salix Pharmaceuticals.

Target Audience

The on-demand presentation will target nurses, nurse practitioners and physician assistants.

Educational Objectives

  • Summarize current best practice in who to screen and most appropriate screening/diagnostics for CLD and thrombocytopenia
  • Explain the pathophysiology in CLD responsible for thrombocytopenia. Describe moderate and severe thrombocytopenia and their clinical implications. Summarize lab tests to measure bleeding.
  • Describe current standard of care for moderate and severe thrombocytopenic patients undergoing elective procedures. Recognize the risks and benefits of this standard in CLD populations.
  • Explain the role of TPO in thrombogenesis and how recent TPO-based drugs increase platelet count.

ANCC Accreditation:

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

A maximum of 1.0 contact hours may be earned for successful completion of this activity.

AANP Accreditation:

This activity has been planned and implemented in accordance with the accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Annenberg Center for Health Sciences and GI Health Foundation. Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.

This program is accredited for 1.0 contact hours. Program ID #5780.

AAPA Accreditation:

    

This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid for one year from 10/31/2019. PAs should only claim credit commensurate with the extent of their participation.

Disclosure of Conflicts of Interest

All individuals in control of the content of continuing education activities provided by the Annenberg Center for Health Sciences at Eisenhower (ACHS) are required to disclose to the audience any real or apparent commercial financial affiliations related to the content of the presentation or enduring material. Full disclosure of all commercial relationships must be made in writing to the audience prior to the activity. Charles Willis, Director of Continuing Education, consults for Pfizer, Inc. All other staff at the Annenberg Center for Health Sciences at Eisenhower and the Chronic Liver Disease Foundation have no relationships to disclose.

Learner Assurance Statement

The Annenberg Center for Health Sciences at Eisenhower is committed to resolving all conflicts of interest issues that could arise as a result of individuals who control activity content and who have significant relationships with drug or device manufacturer(s). The Annenberg Center for Health Sciences at Eisenhower is committed to retaining only those individuals with financial interests that can be reconciled with the goals and educational integrity of the CME activity.

Faculty Disclosure

April Morris, NP
Consultant: AbbVie- Clinical Area- Hepatitis C
Speakers Bureau: Gilead Sciences- Clinical Area- Hepatitis C
Speakers Bureau: AbbVie- Clinical Area- Hepatitis C
Speakers Bureau: Intercept- Clinical Area- PBC

Janet Jezsik, PA
Speakers Bureau: AbbVie- Clinical Area- Hepatitis C
Speakers Bureau: Gilead Sciences- Clinical Area- Hepatitis B, Hepatitis C
Consultant: AbbVie- Clinical Area- Hepatitis C
Consultant: Gilead Sciences- Clinical Area- Hepatitis B, Hepatitis C